• Users Online: 266
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 8  |  Issue : 2  |  Page : 135-139

Can clinical parameters of patients, sans serum prolactin measurement, identify amenorrhea associated with risperidone use? Results from a cross-sectional analytical study

1 Department of Psychiatry, Mahatma Gandhi Medical College and Research Institute, Puducherry, India
2 Department of Psychiatry, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India

Correspondence Address:
Avin Muthuramalingam
Plot No. 45 and 46, 2nd Cross, Gnanapragasam Nagar, Puducherry - 605 008
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrsm.jcrsm_25_22

Rights and Permissions

Background: Risperidone is a second-generation antipsychotic, which exerts its action by antagonizing dopamine (D2) and serotonin (5-HT2A) receptors. Amenorrhea is a common adverse effect observed in risperidone. Risperidone blocks the dopamine receptor of lactotroph cells of the pituitary gland, resulting in loss of the inhibitory effect of dopamine on prolactin. The resultant hyperprolactinemia decreases estrogen through its impact on the pulsatile secretion of gonadotropins and ovarian follicular growth leading to amenorrhea. Identifying the associated clinical parameters will aid in predicting the occurrence of amenorrhea in patients on treatment with risperidone, especially in a setting devoid of prolactin estimation. The objective of this study was to compare the clinical profile of patients with and without risperidone-induced amenorrhea. Methodology: A cross-sectional comparative study was done in a tertiary care hospital. A total of 30 female patients on risperidone who developed amenorrhea were recruited, and age-matched patients on risperidone without amenorrhea were taken as controls. The clinical parameters of the groups were compared using the Mann–Whitney U-test. Binary logistic regression was used to predict the clinical predictors associated with risperidone-induced amenorrhea. Results: The amenorrhea group had a significantly longer duration of untreated psychosis (DUP) (P = 0.011), duration of total treatment (P = 0.003), and duration of treatment exclusively with risperidone (P = 0.002). No significant differences were noted in the dose of risperidone (P = 0.570) and the diagnosis (P = 0.455) between the groups. However, the regression test did not confer any risk due to any clinical parameters. Conclusion: Individuals who developed amenorrhea had a longer DUP and a longer duration of treatment exclusively with risperidone.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal